Canaccord analyst Kingsley Crane raised the firm’s price target on Dynatrace (DT) to $65 from $63 and keeps a Buy rating on the shares. The ...

Despite DeepSeek and Qwen 2.5 disrupting the global tech sector, investors welcomed the impressive Q4 AI revenues from ...

VANCOUVER, BC, Jan. 30, 2025 /CNW/ - Power Metals Corp ("Power Metals" or the "Company") (TSXV: PWM) (FRANKFURT: OAA1) (OTCQB: PWRMF) is pleased to announce the appointment of Canaccord Genuity ...

Canaccord rates Opthea a buy with a $1.25 price target. But the broker thinks it could shoot as high as $3 if a key trial succeeds. But the broker said that with a successful Phase III trial, that ...

(Sharecast News) - Analysts at Canaccord Genuity raised their target price on home improvement retailer Wickes from 180.0p to 198.0p on Wednesday as a "resilient" Q4 performance drove an upgrade ...

As of January 29, 2025, the average one-year price target for Dave is $112.35/share. The forecasts range from a low of $90.90 to a high of $141.75. The average price target represents an increase ...

Q2 2025 Earnings Call February 4, 2025 8:00 AM ETCompany ParticipantsBen Krasinski - Senior Director, IRMichael J.

Jaime Carrasco has joined Harbourfront Wealth Management as senior portfolio manager and senior financial advisor. Carrasco brings his team and more than 25 years of experience in the financial ...

Global Atomic Corporation ("Global Atomic" or the "Company") (TSX: GLO) (OTCQX: GLATF) (FRANKFURT: G12) is pleased to announce the closing of its previously announced non-brokered private placement ...

Canaccord rates Opthea a buy with target of $1.25 – $3 if Phase III trial is successful Opthea’s lead drug shows strong promise in eye disease trials Positive phase III results could lead to big gains ...